TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06408714
Drug: Nalmefene Injection
Normalized name: nalmefene Injection
DrugBank: Nalmefene (DB06230)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects in this arm will be administered intravenous nalmefene with a dosing scheme of:~0.5 mg Nalmefene IV~If an adequate response (increase in RR of at least 5 breaths per minute and minimum respiratory rate of 12 breaths per minute or reduction in ETCO2 to 40 mm Hg) is not attained after 2 minutes, an additional 1.0 mg nalmefene will be administered.~If an adequate response is not attained after an additional 2 minutes of observation, naloxone may be administered as a rescue agent at the treating physician's discretion.
Study: NCT06408714
Drug: Naloxone Injection
Normalized name: naloxone Injection
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects in this arm will be administered intravenous naloxone with a dosing scheme of:~0.4 mg Naloxone IV~If an adequate response (increase in RR of at least 5 breaths per minute and minimum respiratory rate of 12 breaths per minute or reduction in ETCO2 to 40 mm Hg) is not attained after 2 minutes, an additional 0.4 mg of naloxone will be administered.~If an adequate response is not attained after an additional 2 minutes of observation, naloxone may be administered as a rescue agent at the treating physician's discretion.
Study: NCT04656535
Drug: Zimberelimab
Normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimberelimab (AB122) is a fully human immunoglobulin G4 (hIgG4) monoclonal antibody (mAb) that targets PD-1.
Study: NCT04656535
Drug: Domvanalimab
Normalized name: Domvanalimab
DrugBank: Domvanalimab (DB18848)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domvanalimab (AB 154) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets TIGIT.
Study: NCT04704843
Drug: Guselkumab
Normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Guselkumab will be administered as IV infusion (induction dose) and SC injection.
Study: NCT05912517
Drug: Nipocalimab
Normalized name: Nipocalimab
DrugBank: Nipocalimab (DB16257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nipocalimab will be administered as an intravenous infusion.
Study: NCT06061471
Drug: AK111
Normalized name: Alpelisib
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AK111 regimen 1-subcutaneous injection,until week 24.
Study: NCT06061471
Drug: AK111
Normalized name: Alpelisib
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AK111 regimen 2-subcutaneous injection,until week 24.
Study: NCT05873673
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cystic jaw defect filled with coenzyme Q10 gel
Study: NCT04951128
Drug: Tranexamic acid injection
Normalized name: tranexamic acid Injection
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (100 mg/mL concentration; 0.5 mL) will be added to local anesthetic mixture of 2% lidocaine with epinephrine (2.25 mL) and 0.5% bupivacaine with epinephrine (2.25mL).
Study: NCT06303583
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel, 50 mg/m2, QW\*5
Study: NCT06303583
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: area under the curve of2mg/mL/min, QW\*5
Study: NCT06303583
Drug: tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg Q3W, 2cycles
Study: NCT05334654
Drug: Enoxaparin Sodium
Normalized name: Enoxaparin Sodium
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enoxaparin will be subcutaneously administered at a dosage from 4000 to 8000 twice daily according
Study: NCT05334654
Drug: Bivalirudin
Normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bivalirudin will be intravenously administered to obtain an activated prothrombin time (aPTT) of 1.5 fold of the normal values.
Study: NCT05446727
Drug: Ropivacaine injection
Normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30ml of 0.375% ropivacaine
Study: NCT06499857
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3ml pen-injector containing semaglutide 3.0mg/ml solution for subcutaneous use.
Study: NCT06143839
Drug: Vyxeos liposomal
Normalized name: cytarabine liposome / daunorubicin liposomal Injection [Vyxeos]
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard of care JZP351 administered intravenously over 90 minutes.
Study: NCT05094908
Drug: Arnica Tincture
Normalized name: Arnica Tincture
DrugBank: Arnica montana (DB14297)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arnika tincture is a topical plant-based preparation legally authorized in Colombia and in the countries of the European community, the product of this study is Arnika tinktur Gehrlicher (5249), manufactured by Gehrlicher Pharmazeutische Extrakte GmbH, Germany. According to the European Pharmacopoeia, the solution is a 70% hydroethanolic tincture prepared from the flowers of A. montana L, and composed at least 0.04% of sesquiterpene lactones. Arnica tincture will be applied topically by each participant on all lesions until day 30 or 45, depending on the regimen to be evaluated.
Study: NCT06315231
Drug: Edaravone dexborneol sublingual tablet
DrugBank: Borneol (DB11288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive one edaravone dexborneol sublingual tablet twice daily for 24 weeks
Study: NCT05343572
Drug: Plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A 20mg single dose of PLERIXAFOR is administered subcutaneously the evening prior to scheduled standard of care surgery for women with AS, AE or RIF for peripheral mobilization of stem cells. For subjects weighing \>83 kilogram, the dosing is a single dose of 0.24 milligram per kilogram.
Study: NCT04251182
Drug: 15mg T3D-959
Normalized name: Reovirus type 3 (strain dearing) (t3d) (mammalian orthoreovirus 3)
DrugBank: Pelareorep (DB17284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration once daily in the morning
Study: NCT05615818
Drug: Futibatinib
Normalized name: Futibatinib
DrugBank: Futibatinib (DB15149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 20 mg once a day (QD)
Study: NCT05615818
Drug: Ivosidenib
Normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose 500 mg QD
Study: NCT05615818
Drug: Zanidatamab
Normalized name: Zanidatamab
DrugBank: Zanidatamab (DB15471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: Patients \< 70 kg: 1800 mg every 3 weeks (Q3W), Patients ≥ 70 kg: 2400 mg Q3W
Study: NCT05615818
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Loading dose 8 mg/kg, then 6 mg/kg Q3W (Combination with neratinib)
Study: NCT05615818
Drug: Neratinib
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose: 240 mg QD (combination with trastuzumab)
Study: NCT05615818
Drug: Encorafenib
Normalized name: encorafenib
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose: 450 mg QD (Combination with binimetinib)
Study: NCT05615818
Drug: Binimetinib
Normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose: 45 mg twice a day (BID) (Combination with encorafenib)
Study: NCT05615818
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose: 200 mg QD or 300 mg QD
Study: NCT05615818
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose: 25 mg/m2 IV on days 1 and 8 Q3W (CISGEM)
Study: NCT05615818
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose: 1000 mg/m2 IV on days 1 and 8 Q3W (CISGEM)
Study: NCT04251182
Drug: 30 mg T3D-959
Normalized name: Reovirus type 3 (strain dearing) (t3d) (mammalian orthoreovirus 3)
DrugBank: Pelareorep (DB17284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration once daily in the morning
Study: NCT04251182
Drug: 45 mg T3D-959
Normalized name: Reovirus type 3 (strain dearing) (t3d) (mammalian orthoreovirus 3)
DrugBank: Pelareorep (DB17284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration once daily in the morning
Study: NCT04974398
Drug: Penpulimab
Normalized name: Penpulimab
DrugBank: Penpulimab (DB16747)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A: Penpulimab (200 mg, administered on Day 1 of each cycle, Q3W) + cisplatin 80 mg/m2, administered on Day 1 of each cycle, Q3W, up to 6 cycles) + gemcitabine 1000 mg/ m2, administered on Days 1 and 8 of each cycle, Q3W, up to 6 cycles), 3 weeks (21 days) per treatment cycle (Q3W), and then followed by penpulimab monotherapy as maintenance treatment, Q3W.
Study: NCT04606316
Drug: Nivolumab-Placebo
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV) solution that has no therapeutic effect, used as a control in testing investigational drug. One dose is received prior to surgery.
Study: NCT04606316
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given as intravenous (IV) infusion into a vein.
Study: NCT04606316
Drug: Ipilimumab-Placebo
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV) solution that has no therapeutic effect, used as a control in testing investigational drug. One dose is received prior to surgery.
Study: NCT04606316
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given as intravenous (IV) infusion into a vein.
Study: NCT05945927
Drug: Trastuzumab emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab emtansine will be administered as per local clinical practice and local labeling.
Study: NCT05908734
Drug: Cetrelimab
Normalized name: Cetrelimab
DrugBank: Cetrelimab (DB15421)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrelimab will be administered as IV infusion.
Study: NCT05908734
Drug: Amivantamab
Normalized name: amivantamab
DrugBank: Amivantamab (DB16695)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Amivantamab will be administered as IV infusion.
Study: NCT05605899
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT05605899
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT05605899
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously
Study: NCT05605899
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT05605899
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06561958
Drug: REKOVELLE
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Individualised dosing regiment of REKOVELLE in routine clinical practice.
Study: NCT05980117
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam (1.0mg IV) titrated to modified observer's assessment of sedation score of 3 -4 during cataract surgery.
Study: NCT05980117
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam (0.5-2mg IV) titrated to modified observer's assessment of sedation score of 3 - 4 during cataract surgery.
Study: NCT06411028
Drug: botulinum toxin injection (BTX A)
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type B (DB00042)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Three consequetive botulinum toxin injections of the upper extremities
Study: NCT06779396
Drug: The triamcinolone acetonide plus ropivacaine group
Normalized name: Triamcinolone Acetonide
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The solution prepared comprised a mixture of 20mL of 0.2% ropivacaine(40mg) with 4 mg of triamcinolone acetonide. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
Study: NCT06779396
Drug: The ropivacaine group
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The local infiltration solution containing 20mg of 1% ropivacaine. The total volume is 20 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
Study: NCT04799015
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 10mg IV
Study: NCT04799015
Drug: Metoclopramide 10mg
Normalized name: METOCLOPRAMIDE 10MG ORAL DISINTEGRAT TAB
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide 10mg IV
Study: NCT06135415
Drug: Tirbanibulin
Normalized name: TIRBANIBULIN
DrugBank: Tirbanibulin (DB06137)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will apply tirbanibulin ointment topically on the face or balding scalp with AK.
Study: NCT04455750
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04455750
Drug: Rucaparib camsylate
Normalized name: Rucaparib camsylate
DrugBank: Rucaparib (DB12332)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT04455750
Drug: Leuprolide Acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IM
Study: NCT04455750
Drug: Goserelin Acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given SC
Study: NCT04455750
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given SC
Study: NCT06207877
Drug: Cagrilintide
Normalized name: Cagrilintide
DrugBank: Cagrilintide (DB18887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cagrilintide will be administered subcutaneously.
Study: NCT06207877
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide will be administered subcutaneously.
Study: NCT00000862
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06680596
Drug: trastuzumab derxutecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: T-DXd will be administrated as an intra-venous injection of 5.4 mg/kg every three weeks (1 cycle = 21-day treatment).
Study: NCT06667726
Drug: Fluorodopa F 18
Normalized name: FLUORODOPA F-18
DrugBank: Fluorodopa (18F) (DB13848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05775094
Drug: Romosozumab
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romosozumab will be administered 210 mg SC as two 105 mg prefilled syringes once every 4 weeks x 12 months. No dose adjustments for romosozumab will be permitted. All efforts will be made to administer romosozumab within the defined study visit windows (+/- 14 days).
Study: NCT05917509
Drug: Cabotegravir (CAB) LA
DrugBank: Cabotegravir (DB11751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CAB LA will be administered as a gluteal intramuscular injection once every 2 months in combination with RPV LA.
Study: NCT05917509
Drug: Rilpivirine (RPV) LA
Normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RPV LA will be administered as a gluteal intramuscular injection once every 2 months in combination with CAB LA.
Study: NCT02095847
Drug: Proflavine
Normalized name: proflavine
DrugBank: Proflavine (DB01123)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After hysteroscopy with HRME camera, uterine cavity infused with 10 mL of Proflavine.
Study: NCT06205485
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85 mg/m2 or 130 mg/m2 on day 1
Study: NCT06667973
Drug: Gilteritinib
Normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Gilteritinib fumarate is an oral, selective FLT3 and AXL inhibitor. It is a type 1 inhibitor, active against both the FLT3-ITD and FLT3-TKD mutations. Gilteritinib inhibits FLT3 receptor signaling and proliferation in cells exogenously expressing FLT3 including FLT3-ITD, FLT3-D835Y, and FLT3-ITD-D835Y, and it induces apoptosis in leukemic cells expressing FLT3-ITD.~Gilteritinib is approved for the treatment of relpased/refractory FLT3-mutated AML after the successfull ADMIRAL trial. In the present study Gilteritinib (120 mg/die) in combination with FLAI will be tested as induction therapy in newly-diagnosed patients.
Study: NCT05712356
Drug: LSTA1
Normalized name: LSTA1
DrugBank: LSTA1 (DB17346)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSTA1 3.2 mg/kg given as a slow IV push over 1 minute when standard treatment(s) are given
Study: NCT05712356
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1500 mg of durvalumab IV administered over 1 hour every 21 days for 8 cycles then every 28 days for additional cycles
Study: NCT05712356
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin 25 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles
Study: NCT05712356
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: gemcitabine 1000 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles
Study: NCT05546411
Drug: 5-Fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part of the FOLFIRINOX drug combination, given by intravenous infusion
Study: NCT05546411
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part of the FOLFIRINOX drug combination, given by intravenous infusion
Study: NCT05546411
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part of the FOLFIRINOX drug combination, given by intravenous infusion
Study: NCT05042635
Drug: Ixekizumab+Jueyin Granules
DrugBank: Ixekizumab (DB11569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixekizumab：160mg was injected subcutaneously at week 0 (80mg twice), then 80mg at week 2 and 4 (once).~Jueyin Granules：Put each bag of daily dose into the same container, pour about 50ml warm water into it, stir until the particles are basically dissolved, then add proper amount of boiling water to dilute it, take it warm in two times.
Study: NCT05546411
Drug: NIS793
Normalized name: Anti-tgf-beta monoclonal antibody nis793
DrugBank: Nisevokitug (DB17561)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by intravenous infusion
Study: NCT05042635
Drug: Ixekizumab+Jueyin placebo Granules
DrugBank: Ixekizumab (DB11569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixekizumab：160mg was injected subcutaneously at week 0 (80mg twice), then 80mg at week 2 and 4 (once).~Jueyin placebo Granules：Put each bag of daily dose into the same container, pour about 50ml warm water into it, stir until the particles are basically dissolved, then add proper amount of boiling water to dilute it, take it warm in two times.
Study: NCT05153772
Drug: AlphaMedix
Normalized name: Alphamedix
DrugBank: Dotamtate Pb-212 (DB17312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 212Pb-DOTAMTATE is a radiolabeled derivative of octreotide targeting somatostatin positive neuroendocrine tumors
Study: NCT05816720
Drug: Lutetium-177 DOTATATE
Normalized name: Lutetium-177
DrugBank: Dotatate (DB14554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration
Study: NCT05934448
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab via iv, dosage and timing per protocol
Study: NCT05934448
Drug: Lymphodepletion Chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will undergo lymphodepleting chemotherapy (fludarabine, cyclophosphamide) for CAR T-cell therapy as per SOC
Study: NCT05934448
Drug: Chimeric Antigen Receptor (CAR) Therapy Infusion
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 0 in the hospital and will remain in the inpatient setting for observation for a minimum of 7 days or until CAR T-cell toxicities resolve to grade 1 or better. The choice of CAR-T product will be left to the discretion of the treating investigator.
Study: NCT03559673
Drug: Lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will start on the individual Lacosamide (LCM) dose that they had reached at the completion of the previous monotherapy study. LCM will be administered orally twice daily in 2 divided doses.
Study: NCT06584929
Drug: Nicoderm CQ nicotine patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two week supply provided to participants on study.
Study: NCT06584929
Drug: Nicorette Nicotine Lozenges
Normalized name: nicotine Oral Lozenge [Nicorette]
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two week supply provided to participants on study.